Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 2/2020

09.07.2019 | Original Research

Inhibitory Traits of Dendrosome Curcumin (DNC) on Breast Cancer Compared to Curcumin Single Compound

verfasst von: Yasemin Khudiar Alghanimi, Abdolmajid Ghasemian

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Vast therapeutic traits and very low toxicity of curcumin compound have made it and related formulations promising for treatment purposes. The aim of this study was the assessment of dendrosome curcumin (DNC) inhibitory effects on breast cancer therapy compared to single curcumin compound.

Methods

DNC was synthesized and MCF-7 cells were prepared. The cultured cells were treated with 20 μg/ml and 25 μg/ml of DNC. Real-time quantitative PCR (RT-qPCR) was performed to measure the expression of FOXCUT and MEG3 genes. Additionally, flow cytometry was applied to measure cell death rate and apoptosis.

Results

The results outlined that DNC enhanced the MEG3 gene expression significantly higher than the control. Furthermore, DNC was associated with a significant decrease in the expression of FOXCUT gene as compared to the control. The application of DNC in the MCF7 cell line enhanced cell death and reduced necrosis.

Conclusions

The rate of apoptosis (programmed cell death) was enhanced, but necrosis was decreased in treated cancer cells compared to those treated with single curcumin. Accordingly, the DNC can be applied to hinder the growth and dissemination of cancer cells as a preferred approach to reduce the complications of other strategies such as chemotherapy and radiation therapy. Indeed, we concluded that DNC enhanced the expression of MEG3, a tumor suppressor, at 25 μm dose, but reduced the expression of the FOXCUT gene, possibly via the methylation of the gene. Thereby, DNC exerted a promising tumor inhibitory growth potential for the eradication of cancer cells.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMedCrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMedCrossRef
2.
Zurück zum Zitat McGuire S. World cancer report 2014. Geneva: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015: Oxford University Press; 2016. McGuire S. World cancer report 2014. Geneva: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015: Oxford University Press; 2016.
3.
Zurück zum Zitat Carioli G, Malvezzi M, Rodriguez T, Bertuccio P, Negri E, La Vecchia C. Trends and predictions to 2020 in breast cancer mortality: Americas and Australasia. Breast. 2018;37:163–9.PubMedCrossRef Carioli G, Malvezzi M, Rodriguez T, Bertuccio P, Negri E, La Vecchia C. Trends and predictions to 2020 in breast cancer mortality: Americas and Australasia. Breast. 2018;37:163–9.PubMedCrossRef
5.
Zurück zum Zitat Xu Y-z, Chen F-f, Zhang Y, Zhao Q-f, Guan X-l, Wang H-y, et al. The long noncoding RNA FOXCUT promotes proliferation and migration by targeting FOXC1 in nasopharyngeal carcinoma. Tumor Biol. 2017;39(6):1010428317706054. Xu Y-z, Chen F-f, Zhang Y, Zhao Q-f, Guan X-l, Wang H-y, et al. The long noncoding RNA FOXCUT promotes proliferation and migration by targeting FOXC1 in nasopharyngeal carcinoma. Tumor Biol. 2017;39(6):1010428317706054.
6.
Zurück zum Zitat Sreekutty J. Possible mechanism of action of albumin conjugated curcumin on lung cancer cells. Thiruvananthapuram: SCTIMST; 2017. Sreekutty J. Possible mechanism of action of albumin conjugated curcumin on lung cancer cells. Thiruvananthapuram: SCTIMST; 2017.
7.
Zurück zum Zitat Yalameha B. Administration of herbal antioxidant to prevent and treatment of cancers. Ann Res Antioxid. 2018;3(1). Yalameha B. Administration of herbal antioxidant to prevent and treatment of cancers. Ann Res Antioxid. 2018;3(1).
8.
Zurück zum Zitat Nadaf SJ, Killedar SG. Curcumin nanocochleates: use of design of experiments, solid state characterization, in vitro apoptosis and cytotoxicity against breast cancer MCF-7 cells. J Drug Deliv Sci Technol. 2018;47:337–50.CrossRef Nadaf SJ, Killedar SG. Curcumin nanocochleates: use of design of experiments, solid state characterization, in vitro apoptosis and cytotoxicity against breast cancer MCF-7 cells. J Drug Deliv Sci Technol. 2018;47:337–50.CrossRef
9.
Zurück zum Zitat Khosropanah MH, Dinarvand A, Nezhadhosseini A, Haghighi A, Hashemi S, Nirouzad F, et al. Analysis of the antiproliferative effects of curcumin and nanocurcumin in MDA-MB231 as a breast cancer cell line. Iran J Pharm Res. 2016;15(1):231.PubMedPubMedCentral Khosropanah MH, Dinarvand A, Nezhadhosseini A, Haghighi A, Hashemi S, Nirouzad F, et al. Analysis of the antiproliferative effects of curcumin and nanocurcumin in MDA-MB231 as a breast cancer cell line. Iran J Pharm Res. 2016;15(1):231.PubMedPubMedCentral
10.
Zurück zum Zitat Mukerjee A, Ranjan AP, Vishwanatha JK. Targeted nanocurcumin therapy using Annexin A2 antibody improves tumor accumulation and therapeutic efficacy against highly metastatic breast cancer. J Biomed Nanotechnol. 2016;12(7):1374–92.PubMedCrossRef Mukerjee A, Ranjan AP, Vishwanatha JK. Targeted nanocurcumin therapy using Annexin A2 antibody improves tumor accumulation and therapeutic efficacy against highly metastatic breast cancer. J Biomed Nanotechnol. 2016;12(7):1374–92.PubMedCrossRef
11.
Zurück zum Zitat Arora R, Kuhad A, Kaur I, Chopra K. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats. Eur J Pain. 2015;19(7):940–52.PubMedCrossRef Arora R, Kuhad A, Kaur I, Chopra K. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats. Eur J Pain. 2015;19(7):940–52.PubMedCrossRef
12.
Zurück zum Zitat Brantl S. Regulatory mechanisms employed by cis-encoded antisense RNAs. Curr Opin Microbiol. 2007;10(2):102–9.PubMedCrossRef Brantl S. Regulatory mechanisms employed by cis-encoded antisense RNAs. Curr Opin Microbiol. 2007;10(2):102–9.PubMedCrossRef
13.
Zurück zum Zitat Mattick JS, Rinn JL. Discovery and annotation of long noncoding RNAs. Nat Struct Mol Biol. 2015;22(1):5–7.PubMedCrossRef Mattick JS, Rinn JL. Discovery and annotation of long noncoding RNAs. Nat Struct Mol Biol. 2015;22(1):5–7.PubMedCrossRef
14.
Zurück zum Zitat Guo W, Dong Z, Shi Y, Liu S, Liang J, Guo Y, et al. Aberrant methylation-mediated downregulation of long noncoding RNA LOC100130476 correlates with malignant progression of esophageal squamous cell carcinoma. Dig Liver Dis. 2016;48(8):961–9.PubMedCrossRef Guo W, Dong Z, Shi Y, Liu S, Liang J, Guo Y, et al. Aberrant methylation-mediated downregulation of long noncoding RNA LOC100130476 correlates with malignant progression of esophageal squamous cell carcinoma. Dig Liver Dis. 2016;48(8):961–9.PubMedCrossRef
15.
Zurück zum Zitat Dhamija S, Diederichs S. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer. 2016;139(2):269–80.PubMedCrossRef Dhamija S, Diederichs S. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer. 2016;139(2):269–80.PubMedCrossRef
16.
Zurück zum Zitat Jiang C, Li X, Zhao H, Liu H. Long non-coding RNAs: potential new biomarkers for predicting tumor invasion and metastasis. Mol Cancer. 2016;15(1):62.PubMedPubMedCentralCrossRef Jiang C, Li X, Zhao H, Liu H. Long non-coding RNAs: potential new biomarkers for predicting tumor invasion and metastasis. Mol Cancer. 2016;15(1):62.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Sannigrahi M, Sharma R, Panda N, Khullar M. Role of non-coding RNA s in head and neck squamous cell carcinoma: a narrative review. Oral Dis. 2018;24(8):1417–27.PubMedCrossRef Sannigrahi M, Sharma R, Panda N, Khullar M. Role of non-coding RNA s in head and neck squamous cell carcinoma: a narrative review. Oral Dis. 2018;24(8):1417–27.PubMedCrossRef
18.
Zurück zum Zitat Saadipoor A, Razzaghdoust A, Simforoosh N, Mahdavi A, Bakhshandeh M, Moghadam M, et al. Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy. Phytother Res. 2018;33(2):370–378 https://doi.org/10.1002/ptr.6230.. Saadipoor A, Razzaghdoust A, Simforoosh N, Mahdavi A, Bakhshandeh M, Moghadam M, et al. Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy. Phytother Res. 2018;33(2):370–378 https://​doi.​org/​10.​1002/​ptr.​6230.​.
19.
Zurück zum Zitat Xie M, Fan D, Zhao Z, Li Z, Li G, Chen Y, et al. Nano-curcumin prepared via supercritical: improved anti-bacterial, anti-oxidant and anti-cancer efficacy. Int J Pharm. 2015;496(2):732–40.PubMedCrossRef Xie M, Fan D, Zhao Z, Li Z, Li G, Chen Y, et al. Nano-curcumin prepared via supercritical: improved anti-bacterial, anti-oxidant and anti-cancer efficacy. Int J Pharm. 2015;496(2):732–40.PubMedCrossRef
Metadaten
Titel
Inhibitory Traits of Dendrosome Curcumin (DNC) on Breast Cancer Compared to Curcumin Single Compound
verfasst von
Yasemin Khudiar Alghanimi
Abdolmajid Ghasemian
Publikationsdatum
09.07.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 2/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00273-2

Weitere Artikel der Ausgabe 2/2020

Journal of Gastrointestinal Cancer 2/2020 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.